CEAP 6级患者VenaSeal与ClosureFast大隐静脉闭合后穿通支治疗需求比较
多机构回顾性研究纳入2015-2020年119例CEAP 6级下肢,VenaSeal组51肢、RFA组68肢,比较大隐静脉闭合后穿通支干预需求。
要点
- VenaSeal组伤口愈合中位时间43天,短于RFA组104天。
- RFA组后续穿通支干预比例49%,高于VenaSeal组27%。
- 两组在 concurrent 硬化剂治疗使用上无差异。
核心结论
- ClosureFast和VenaSeal均为有效且安全的大隐静脉闭合方式。
- VenaSeal治疗与较少的穿通支RFA干预相关。
研究设计与样本
- 多机构回顾性综述,纳入2015至2020年接受大隐静脉闭合的CEAP 6级患者。
- 共119例CEAP 6级患者:VenaSeal组51肢,RFA组68肢。
- 中位随访105天(四分位距44,208)。
主要发现
- 所有肢体在研究期间均实现伤口愈合。
- VenaSeal组平均伤口愈合时间72天,RFA组293.8天(P > .0009);中位时间分别为43天和104天(P = .001)。
- RFA组既往已知深静脉血栓比例29% vs VenaSeal组10%(P = .009)。
- RFA组深静脉功能不全比例82% vs 51%(P = .0003),穿通支反流比例57% vs 29%(P = .002)。
- 存在随访穿通支反流并接受治疗的肢体中,初始RFA治疗比例49% vs VenaSeal组27%(P = .003)。
临床怎么用
- 对于CEAP 6级静脉性溃疡患者,VenaSeal大隐静脉闭合可能减少后续穿通支干预需求。
- 选择闭合方式时需考虑患者是否合并深静脉血栓、深静脉功能不全及穿通支反流。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors have previously demonstrated that VenaSeal (Medtronic, Inc, Minneapolis, Minn) adhesive, compared with radiofrequency ablation (RFA, ClosureFast; Medtronic, Inc), in treatment of refluxing saphenous veins in CEAP 6 limbs, results in shorter healing times of venous ulcers. The authors hypothesize that the longer treated length possible with VenaSeal's nonthermal modality may affect the number of critical refluxing perforators contributing to the nonhealing wound. This follow-up study compares the need for follow-up treatment of perforator veins after saphenous vein treatment with either radiofrequency ablation (ClosureFast RFA) or adhesive closure (VenaSeal). METHODS: A multi-institutional retrospective review of CEAP 6 patients who had closure of their saphenous veins from 2015 to 2020 was conducted. Patients who underwent follow-up treatment of perforator veins were grouped according to their method of initial management of their saphenous veins. The primary end point was incidence of a perforator procedure after ClosureFast or VenaSeal ablation. Secondary end points included sclerotherapy to facilitate wound healing. Bivariate analysis used the χ2 test, Fisher exact test, t-test, and Wilcoxon rank sum test. A P value of <.05 defined statistical significance. RESULTS: There were 119 CEAP 6 patients with saphenous closure: 51 limbs treated with VenaSeal and 68 with RFA. Median follow-up was 105 days (interquartile range: 44, 208). All limbs achieved wound healing during the study period. Mean time to wound healing post index procedure was shorter for VenaSeal than RFA (72 vs 293.8 days, P > .0009), as was median time (43 vs 104 days, P = .001). More limbs treated with RFA had previous known deep vein thrombosis (29% vs 10%, P = .009), deep venous insufficiency (82% vs 51%, P = .0003), and perforator reflux (57% vs 29%, P = .002). Limbs with identified follow-up perforator reflux treated with RFA had a higher prevalence of initially treated saphenous veins with RFA compared with those treated with VenaSeal (49% vs 27%, P = .003). There was no difference between the methods of vein closure and use of concurrent sclerotherapy. CONCLUSIONS: ClosureFast and VenaSeal are both effective and safe modalities of saphenous ablation, but VenaSeal treatment was associated with less perforator RFA intervention.
引用
- Kiguchi MM, Reynolds KB, Cutler B, et al. The need for perforator treatment after VenaSeal and ClosureFast endovenous saphenous vein closure in CEAP 6 patients. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34111593. doi:10.1016/j.jvsv.2021.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。